What is Certara?
Certara operates at the intersection of software, artificial intelligence, and scientific consulting, providing a comprehensive suite of solutions that span the entire drug development lifecycle. From initial discovery and preclinical modeling to navigating complex clinical trials, securing regulatory approvals, and optimizing market access, Certara's offerings are designed to enhance efficiency and predictability. The company's core expertise lies in model-informed drug development (MIDD) and advanced biosimulation technologies, which empower pharmaceutical and biotechnology firms to forecast drug behavior, optimize therapeutic strategies, and ultimately improve patient outcomes. This strategic focus positions Certara as a critical partner for organizations seeking to de-risk and expedite the development of novel therapeutics.
How much funding has Certara raised?
Certara has raised a total of $1.4B across 4 funding rounds:
Stock Offering
$668M
Stock Offering
$310M
Private Equity
$449M
Private Equity
$8.6M
Stock Issuance/Offering (2020): $668M with participation from Undisclosed
Stock Issuance/Offering (2021): $310M, investors not publicly disclosed
Private Equity (2022): $449M supported by Arsenal Capital Partners
Private Equity (2026): $8.6M, investors not publicly disclosed
Key Investors in Certara
Arsenal Capital Partners
Arsenal Capital Partners is a private equity firm specializing in middle-market industrial growth and healthcare companies. They focus on high-growth, technology-rich businesses and employ a team of industry executives and scientists to execute complex growth strategies.
What's next for Certara?
With the infusion of $8.6M in a major strategic investment, Certara is poised for significant advancements. This enterprise-level backing suggests a focus on scaling its AI-driven platforms and expanding its global reach in scientific consulting services. The company is likely to further enhance its biosimulation capabilities and integrate more sophisticated predictive analytics into its software solutions. Strategic acquisitions or partnerships to broaden its technology portfolio and market penetration are also probable. Certara's trajectory indicates a commitment to solidifying its leadership in model-informed drug development, aiming to accelerate the delivery of life-saving medicines to patients worldwide.
See full Certara company page
